ADRIAAN W. DEKKER, M.D.; MAJA ROZENBERG-ARSKA, M.D.; JAN VERHOEF, M.D.
Fifty-six patients receiving remission induction treatment for acute leukemia were studied in a randomized trial comparing ciprofloxacin with trimethoprim-sulfamethoxazole plus Colistin for prevention of infections. Both groups received amphotericin B for antifungal prophylaxis. Six major infections occurred in 28 patients receiving ciprofloxacin, and 11 major infections occurred in 28 patients receiving trimethoprim-sulfamethoxazole plus Colistin. No infections caused by gram-negative bacilli were seen in the ciprofloxacin group (p < 0.02). Ciprofloxacin prevented colonization with resistant gram-negative bacilli, but 12 resistant colonizing strains were isolated from 10 patients receiving trimethoprim-sulfamethoxazole plus Colistin (p < 0.01). Ciprofloxacin was better tolerated: 23 of 28 patients were highly compliant to the drug, compared with 15 of 28 patients in the trimethoprim-sulfamethoxazole group (p < 0.05). These results suggest that ciprofloxacin is a promising drug for the prevention of infection in patients with granulocytopenia.
DEKKER AW, ROZENBERG-ARSKA M, VERHOEF J. Infection Prophylaxis in Acute Leukemia: A Comparison of Ciprofloxacin with Trimethoprim-Sulfamethoxazole and Colistin. Ann Intern Med. ;106:7–12. doi: 10.7326/0003-4819-106-1-7
Download citation file:
Published: Ann Intern Med. 1987;106(1):7-12.
Hematology/Oncology, Infectious Disease, Leukemia/Lymphoma.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use